<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252846</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-M044-512</org_study_id>
    <nct_id>NCT04252846</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants &gt;=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy</brief_title>
  <official_title>A Prospective, Non-Interventional, Observational, Multicenter Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Adjunctive Therapy in the Routine Clinical Care of Subjects &gt;=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the retention rate of perampanel as a reliable
      proxy for overall effectiveness and tolerability in participants aged at least 12 years who
      are prescribed perampanel (for partial onset seizures [POS] with or without secondary
      generalization [SG] or for primary generalized tonic-clonic seizures [PGTCS] associated with
      idiopathic generalized epilepsy [IGE] as first adjunctive to antiepileptic drug (AED)
      monotherapy as part of their routine clinical care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retention Rate at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Retention rate at 12 months is defined as the percentage of participants remaining on perampanel at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention Rate at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Retention rate at 6 months is defined as the percentage of participants remaining on perampanel at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pragmatic Seizure-free Rate at Months 6 and 12</measure>
    <time_frame>Months 6 and 12</time_frame>
    <description>Pragmatic seizure-free rate is defined as the percentage of participants (based on all study participants) who are free of all seizures at 6 months (and for the previous 3 months) and at 12 months (and for the previous 6 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completer Seizure-free Rate at Months 6 and 12</measure>
    <time_frame>Months 6 and 12</time_frame>
    <description>Completer seizure-free rate is defined as the percentage of participants (based on a subset of study participants who remain on perampanel treatment at 6 and 12 months) who are free of all seizures at 6 months (and for the previous 3 months) and at 12 months (and for the previous 6 months), respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in Seizure Frequency at Months 6 and 12</measure>
    <time_frame>Months 6 and 12</time_frame>
    <description>Seizure frequency change will be measured at 6 months (averaged over the previous 3 months) and at 12 months (averaged over the previous 6 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50 Percent (%) Responder Rate at Months 6 and 12</measure>
    <time_frame>Months 6 and 12</time_frame>
    <description>50% responder rate is defined as the percentage of participants with greater than or equal to (&gt;=) 50% reduction in seizure frequency (averaged over the 3 months before the 6-month visit, and over the 6 months before the12-month visit) relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure Worsening Rate at Months 6 and 12</measure>
    <time_frame>Months 6 and 12</time_frame>
    <description>Seizure worsening rate is defined as the percentage of participants with &gt;=10% increase in seizure frequency (averaged over the 3 months before the 6-month visit, and over the 6 months before the 12-month visit) relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Dose of Perampanel at Months 6 and 12</measure>
    <time_frame>Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Perampanel Dose Titration Speed</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment on Perampanel</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs),Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation, and TEAEs by Severity</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Idiopathic Generalized Epilepsy</condition>
  <condition>Partial Onset Seizures</condition>
  <condition>Generalised Tonic-Clonic Seizures</condition>
  <arm_group>
    <arm_group_label>Perampanel</arm_group_label>
    <description>Participants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>Perampanel oral tablets or oral suspension.</description>
    <arm_group_label>Perampanel</arm_group_label>
    <other_name>Fycompa</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 300 participants with diagnosis of epilepsy (POS with or without SG or PGTCS
        associated with IGE)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of epilepsy

          2. History of POS with or without SG or PGTCS associated with IGE

          3. Documented POS with or without SG or PGTCS associated with IGE, within the past 12
             months

          4. Previously treated with 1 or 2 AEDs as monotherapy

          5. At least 4 weeks' seizure diary data, or sufficient clinical detail to calculate
             baseline seizure frequency

        Exclusion Criteria:

          1. Episode(s) of status epilepticus within the past 6 months before Screening

          2. Previously treated with 2 or more AEDs in combination (other than during
             cross-titration between AED monotherapies)

          3. Previous or current use of perampanel

             Note: Retrospective inclusions will be allowed but only if the time between the
             initiation of perampanel treatment and the inclusion does not exceed 7 calendar days

          4. Hypersensitivity to perampanel or any of the excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <email>EUMedInfo@eisai.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christian-Doppler-Klinik Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Dianalund</city>
        <state>Sjælland</state>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <state>South Denmark</state>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de consultations Saint-Jean Bâtiment A</name>
      <address>
        <city>Cagnes-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux de La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN A Cardarelli</name>
      <address>
        <city>Naples</city>
        <state>Campania</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Merano</name>
      <address>
        <city>Merano</city>
        <state>Trentino-Alto Adige</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Ospedale Policlinico Consorziale Di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico Di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar E Universitário de Coimbra EPE</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University n.a. V.F. Voyno-Ysenetskiy</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1 n.a. N.I.Pirogov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University n.a. N.I.Pirogov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Neurology Center Sibneuromed LLC</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Treatment and Rehabilitation Center</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUVI - H.U. Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sagrat Cor Quironsalud</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - PPDS</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga - Hospital General</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital - PPDS</name>
      <address>
        <city>Glasgow</city>
        <state>Glasgow City</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Gwent Hospital - PPDS</name>
      <address>
        <city>Newport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perampanel</keyword>
  <keyword>Fycompa</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Seizures</keyword>
  <keyword>Prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy, Generalized</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

